Top Markets
#1 Islamic Coin Islamic Coin +154.45%
#2 PulseChain PulseChain +49.22%
#3 RedStone RedStone +23.10%
#4 MarsCoin MarsCoin +14.90%
#5 BOOK OF MEME BOOK OF MEME +14.69%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.37%
#7 Nockchain Nockchain +11.14%
#8 Starpower Starpower +9.36%
#9 Venom Venom +9.22%
#10 Lighter Lighter +9.20%
Coin of the day
Islamic Coin Islamic Coin
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Clasificación en acciones #28047
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Precio por acción
$0.55
Última sincronización: 2025-02-11
Capitalización bursátil
$28.90M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Marinus Pharmaceuticals, Inc. (MRNS)

Categoría

Healthcare
Ratio P/S de Marinus Pharmaceuticals, Inc. (MRNS)
Ratio P/S al August 2026 TTM: 0.98
Según los informes financieros más recientes y el precio de las acciones de Marinus Pharmaceuticals, Inc., el ratio P/S actual (TTM) es 0.98. Al final de 2022, el ratio P/S era 1.53.
Historial del ratio P/S de Marinus Pharmaceuticals, Inc. desde 2012 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
2026 (TTM) 0.98 -79.24%
2023 4.72 209.16%
2022 1.53 -78.52%
2021 7.10 -85.33%
2020 48.41 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 -100.00%
2012 161.27 0.00%
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 937.53%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 1,050.68%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 933.60%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 201.18%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH